Abstract
Amide and ester conjugates of aceclofenac with polyamidoamine (PAMAM-G0) dendrimer zero generation and dextran (40 kDa) polymeric carrier, respectively, are presented. The prepared conjugates were characterized by UV, TLC, HPLC, IR, and 1H NMR spectroscopy. The average degrees of substitution of amide and ester conjugates were determined and found to be (12.5 ± 0.24) % and (7.5 ± 0.25) %, respectively. The in vitro hydrolysis studies showed that dextran ester conjugate hydrolyzed faster in a phosphate buffer solution of pH 9.0 as compared to PAMAM dendrimer G0 amide conjugate, and followed the first order kinetics. No amount of the drug was regenerated at pH 1.2 in simulated gastric fluid. The dextran conjugate showed short half-life as compared to the PAMAM dendrimer conjugate. Anti-inflammatory and analgesic activities of the dendrimer conjugate were found to be similar to those of the standard drug. Results of chronic ulceroginic activity showed deep ulceration and high ulcer index for aceclofenac, whereas lower ulcer index was found for the PAMAM dendrimer and dextran (40 kDa) conjugates. Experimental data suggest that PAMAM dendrimer and dextran (40 kDa) can be used as carriers for the sustained delivery of aceclofenac along with a remarkable reduction in gastrointestinal toxicity.
Similar content being viewed by others
References
Asthana, A., Chauhan, A. S., Diwan, P. V., & Jain, N. K. (2005). Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech, 6, E535–E542. DOI: 10.1208/pt060367.
Burkhard, H., Thomas, R., Daniel, A., Ulrike, W., Robert, R., Stephan, R., & Kay, B. (2003). Aceclofenac spares cyclooxygenase-1 as a result of limited but sustained biotransformation to diclofenac. Journal of Clinical Pharmacy and Therapeutics, 74, 222–235. DOI: 10.1016/S0009- 9236(03)00167-X.
Chauhan, A. S., Diwan, P. V., Jain, N. K., & Tomalia, D. A. (2009). Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules, 10, 1195–1202. DOI: 10.1021/bm9000298.
Cheng, Y., Gao, Y., Rao, T., Li, Y., & Xu, T. (2007a). Dendrimer-based prodrugs: Design, synthesis, screening and biological evaluation. Combinatorial Chemistry & High Throughput Screening, 10, 336–349. DOI: 10.2174/138620707781662808.
Cheng, Y., Man, N., Xu, T., Fu, R., Wang, X., Wang, X., & Wen, L. (2007b). Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. Journal of Pharmaceutical Sciences, 96, 595–602. DOI: 10.1002/jps.20745.
Cheng, Y., & Xu, T. (2008). The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of noncovalently or covalently attached drugs. European Journal of Medicinal Chemistry, 43, 2291–2297. DOI: 10.1016/j.ejmech.2007.12.021.
Cheng, Y., & Xu, T. (2005). Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. European Journal of Medicinal Chemistry, 40, 1188–1192. DOI:10.1016/j.ejmech.2005.06.010.
Cheng, Y., Xu, T., & Fu, R. (2005). Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. European Journal of Medicinal Chemistry, 40, 1390–1393. DOI:10.1016/j.ejmech.2005.08.002.
Cheng, Y., Xu, Z., Ma, M., & Xu, T. (2008). Dendrimer as drug carrier: Application in different routes of drug administration. Journal of Pharmaceutical Sciences, 97, 123–143. DOI: 10.1002/jps.21079.
Davies, O. L., Raventós, J., & Walpole, A. L. (1946). A method for the evaluation of analgesic activity using rats. British Journal of Pharmacology, 1, 255–264.
Feldman, M., & McMahon, A. T. (2000). Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Annals of Internal Medicine, 132, 134–143.
Gajbhiye, V., Kumar, P. V., Tekade, R. K., & Jain, N. K. (2009). PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. European Journal of Medicinal Chemistry, 44, 1155–1166. DOI: 10.1016/j.ejmech.2008.06.012.
Giannuzzo, M., Corrente, F., Feeney, M., Paoletti, L., Paolicelli, P., Tita, B., Vitali, F., & Casadei, M. A. (2008). pH-Sensitive hydrogels of dextran: Synthesis, characterization and in vivo studies. Journal of Drug Targeting, 16, 649–659. DOI: 10.1080/10611860802201191.
Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K., & Isakson, P. C. (1999). Kinetic basis for selective inhibition of cyclo-oxygenases. Biochemical Journal, 339, 607–614. DOI:10.1042/0264-6021:3390607.
Gurdag, S., Khandare, J., Stapels, S., Matherly, L. H., & Kannan, R. M. (2006). Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjugate Chemistry, 17, 275–283. DOI: 10.1021/bc0501855.
Hoste, K., De Winne, K., & Schacht, E. (2004). Polymeric prodrugs. International Journal of Pharmaceutics, 277, 119–131. DOI: 10.1016/j.ijpharm.2003.07.016.
Jung, Y. J., Lee, J. S., Kim, H. H., Kim, Y. T., & Kim, Y. M. (1998). Synthesis and properties of dextran-5-aminosalicyclic acid ester as a potential colon-specific prodrug of 5-aminosalicyclic acid. Archives of Pharmacal Research, 21, 179–186.
Khandare, J., & Minko, T. (2006). Polymer-drug conjugates: Progress in polymeric prodrugs. Progress in Polymer Science, 31, 359–397. DOI: 10.1016/j.progpolymsci.2005.09.004.
Larsen, C. (1990). Dextran prodrugs—Physicochemical and chemical aspects in relation to in-vivo properties. Unpublished DSc. thesis. Copenhagen, Denmark: Villadsen & Christensen.
Larsen, C., Harboe, E., Johansen, M., & Olesen, H. P. (1989). Macromolecular prodrugs. XVI. Colon-targeted delivery—comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharmaceutical Research, 6, 995–999. DOI: 10.1023/A:1015914101233.
Lee, J. S., Jung, Y. J., Doh, M. J., & Kim, Y. M. (2001). Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Development and Industrial Pharmacy, 27, 331–336. DOI: 10.1081/DDC-100103732.
Man, N., Cheng, Y., Xu, T., Ding, Y., Wang, X., Li, Z., Chen, Z., Huang, G., Shi, Y., & Wen, L. (2006). Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. European Journal of Medicinal Chemistry, 41, 670–674. DOI: 10.1016/j.ejmech.2006.01.001.
Mehvar, R. (2000). Dextrans for targeted and sustained delivery of therapeutic and imaging agents. Journal of Controlled Release, 69, 1–25. DOI: 10.1016/S0168-3659(00)00302-3.
Mehvar, R. (1999). Simultaneous analysis of dextran-methylprednisolone succinate methylprednisolone succinate, and methylprednisolone by size-exclusion chromatography. Journal of Pharmaceutical and Biomedical Analysis, 19, 785–792. DOI: 10.1016/S0731-7085(98)00308-2.
Mehvar, R., Robinson, M. A., & Reynolds, J. M. (1994). Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. Journal of Pharmaceutical Sciences, 83, 1495–1499. DOI: 10.1002/jps.2600831024.
Musmade, P., Subramanian, G., & Srinivasan, K. K. (2007). High-performance liquid chromatography and pharmacokinetics of aceclofenac in rats. Analytica Chimica Acta, 585, 103–109. DOI: 10.1016/j.aca.2006.11.080.
Najlah, M., Freeman, S., Attwood, D., & D’Emanuele, A. (2006). Synthesis, characterization and stability of dendrimer prodrugs. International Journal of Pharmaceutics, 308, 175–182. DOI: 10.1016/j.ijpharm.2005.10.033.
Rainsford, K. D. (1975). A synergistic interaction between aspirin, or other non-steroidal anti-inflammatory drugs, and stress which produces severe gastric mucosal damage in rats and pigs. Agents actions, 5, 553–558. DOI:10.1007/BF01972694.
Semble, E. L., Wu, W. C. (1987). Antiinflammatory drugs and gastric mucosal damage. Seminars in Arthritis and Rheumatism, 16, 271–286. DOI: 10.1016/0049-0172(87)90005-9.
Shrivastava, S. K., Jain, D. K., & Trivedi, P. (2003a). Dextranspotential polymeric drug carriers for suprofen. Die Pharmazie, 58, 804–806.
Shrivastava, S. K., Jain, D. K., & Trivedi, P. (2003b). Dextranspotential polymeric drug carriers for flurbiprofen. Die Pharmazie, 58, 389–391.
Shrivastava, S. K., Shrivastava, P. K., Jain, D. K., Trivedi, P. (2009). Flurbiprofen- and suprofen-dextran conjugates: Synthesis, characterization and biological evaluation. Tropical Journal of Pharmaceutical Research, 8, 221–229.
Svenson, S., & Tomalia, D. A. (2005). Dendrimers in biomedical applications—reflections on the field. Advanced Drug Delivery Reviews, 57, 2106–2129. DOI: 10.1016/j.addr.2005.09.018.
Sweetman, S. C. (2007). Martindale: The complete drug reference (35th ed., pp. 11–12). London, UK: Pharmaceutical Press.
Tomalia, D. A., & Fréchet, J. M. (2005). Introduction to “dendrimers and dendritic polymers”. Progress in Polymer Science, 30, 217–219. DOI: 10.1016/j.progpolymsci.2005.03.003.
Tomalia, D. A., Naylor, A. M., & Goddard, W. A. (1990). Starburst dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angewandte Chemie International Edition, 29, 138–175. DOI: 10.1002/anie.199001381.
Vane, J. (1994). Towards a better aspirin. Nature, 367, 215–216. DOI: 10.1038/367215a0.
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proceedings of the National Academy of Sciences, 96, 7563–7568.
Winter, C. A., Risley, E. A., & Nuss, G.W. (1962). Carrageenan induced oedema in the hind paw of the rat as an assay for anti-inflammatory drugs. Proceedings of the Society for Experimental Biology and Medicine, 111, 544–547.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shrivastava, P.K., Singh, R. & Shrivastava, S.K. Polyamidoamine dendrimer and dextran conjugates: preparation, characterization, and in vitro and in vivo evaluation. Chem. Pap. 64, 592–601 (2010). https://doi.org/10.2478/s11696-010-0042-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2478/s11696-010-0042-6